Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer

Lauren Averett Byers, Banibrata Sen, Babita Saigal, Lixia Diao, Jing Wang, Meera Nanjundan, Tina Cascone, Gordon Mills, John V. Heymach, Faye M. Johnson

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Purpose: Signal transducer and activator of transcription-3 (STAT3) is downstream of growth factor and cytokine receptors, and regulates key oncogenic pathways in non-small cell lung cancer (NSCLC). Activation of STAT3 by cellular Src (c-Src) promotes tumor progression. We hypothesized that c-Src inhibition could activate STAT3 by inducing a homeostatic feedback loop, contributing to c-Src inhibitor resistance. Experimental Design: The effects of c-Src inhibition on total and phosphorylated STAT3 were measured in NSCLC cell lines and in murine xenograft models by Western blotting. c-Src and STAT3 activity as indicated by phosphorylation was determined in 46 human tumors and paired normal lung by reverse phase protein array. Modulation of dasatinib (c-Src inhibitor) cytotoxicity by STAT3 knockdown was measured by MTT, cell cycle, and apoptosis assays. Results: Depletion of c-Src by small interfering RNA or sustained inhibition by dasatinib increased pSTAT3, which could be blocked by inhibition of JAK. Similarly, in vivo pSTAT3 levels initially decreased but were strongly induced after sustained dasatinib treatment. In human tumors, phosphorylation of the autoinhibitory site of c-Src (Y527) correlated with STAT3 phosphorylation (r = 0.64; P = 2.5 x 10-6). STAT3 knockdown enhanced the cytotoxicity of dasatinib. Conclusions: c-Src inhibition leads to JAK-dependent STAT3 activation in vitro and in vivo. STAT3 knockdown enhances the cytotoxicity of dasatinib, suggesting a compensatory pathway that allows NSCLC survival. Data from human tumors showed a reciprocal regulation of c-Src and STAT3 activation, suggesting that this compensatory pathway functions in human NSCLC. These results provide a rationale for combining c-Src and STAT3 inhibition to improve clinical responses.

Original languageEnglish (US)
Pages (from-to)6852-6861
Number of pages10
JournalClinical Cancer Research
Volume15
Issue number22
DOIs
StatePublished - Nov 15 2009
Externally publishedYes

Fingerprint

STAT3 Transcription Factor
Non-Small Cell Lung Carcinoma
Phosphorylation
Transcriptional Activation
Neoplasms
Protein Array Analysis
Cytokine Receptors
Growth Factor Receptors
Heterografts
Small Interfering RNA
Cell Cycle
Research Design

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Byers, L. A., Sen, B., Saigal, B., Diao, L., Wang, J., Nanjundan, M., ... Johnson, F. M. (2009). Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clinical Cancer Research, 15(22), 6852-6861. https://doi.org/10.1158/1078-0432.CCR-09-0767

Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. / Byers, Lauren Averett; Sen, Banibrata; Saigal, Babita; Diao, Lixia; Wang, Jing; Nanjundan, Meera; Cascone, Tina; Mills, Gordon; Heymach, John V.; Johnson, Faye M.

In: Clinical Cancer Research, Vol. 15, No. 22, 15.11.2009, p. 6852-6861.

Research output: Contribution to journalArticle

Byers, LA, Sen, B, Saigal, B, Diao, L, Wang, J, Nanjundan, M, Cascone, T, Mills, G, Heymach, JV & Johnson, FM 2009, 'Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer', Clinical Cancer Research, vol. 15, no. 22, pp. 6852-6861. https://doi.org/10.1158/1078-0432.CCR-09-0767
Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M et al. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clinical Cancer Research. 2009 Nov 15;15(22):6852-6861. https://doi.org/10.1158/1078-0432.CCR-09-0767
Byers, Lauren Averett ; Sen, Banibrata ; Saigal, Babita ; Diao, Lixia ; Wang, Jing ; Nanjundan, Meera ; Cascone, Tina ; Mills, Gordon ; Heymach, John V. ; Johnson, Faye M. / Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. In: Clinical Cancer Research. 2009 ; Vol. 15, No. 22. pp. 6852-6861.
@article{8de36c7cf11e4c738dea9612af7e5d39,
title = "Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer",
abstract = "Purpose: Signal transducer and activator of transcription-3 (STAT3) is downstream of growth factor and cytokine receptors, and regulates key oncogenic pathways in non-small cell lung cancer (NSCLC). Activation of STAT3 by cellular Src (c-Src) promotes tumor progression. We hypothesized that c-Src inhibition could activate STAT3 by inducing a homeostatic feedback loop, contributing to c-Src inhibitor resistance. Experimental Design: The effects of c-Src inhibition on total and phosphorylated STAT3 were measured in NSCLC cell lines and in murine xenograft models by Western blotting. c-Src and STAT3 activity as indicated by phosphorylation was determined in 46 human tumors and paired normal lung by reverse phase protein array. Modulation of dasatinib (c-Src inhibitor) cytotoxicity by STAT3 knockdown was measured by MTT, cell cycle, and apoptosis assays. Results: Depletion of c-Src by small interfering RNA or sustained inhibition by dasatinib increased pSTAT3, which could be blocked by inhibition of JAK. Similarly, in vivo pSTAT3 levels initially decreased but were strongly induced after sustained dasatinib treatment. In human tumors, phosphorylation of the autoinhibitory site of c-Src (Y527) correlated with STAT3 phosphorylation (r = 0.64; P = 2.5 x 10-6). STAT3 knockdown enhanced the cytotoxicity of dasatinib. Conclusions: c-Src inhibition leads to JAK-dependent STAT3 activation in vitro and in vivo. STAT3 knockdown enhances the cytotoxicity of dasatinib, suggesting a compensatory pathway that allows NSCLC survival. Data from human tumors showed a reciprocal regulation of c-Src and STAT3 activation, suggesting that this compensatory pathway functions in human NSCLC. These results provide a rationale for combining c-Src and STAT3 inhibition to improve clinical responses.",
author = "Byers, {Lauren Averett} and Banibrata Sen and Babita Saigal and Lixia Diao and Jing Wang and Meera Nanjundan and Tina Cascone and Gordon Mills and Heymach, {John V.} and Johnson, {Faye M.}",
year = "2009",
month = "11",
day = "15",
doi = "10.1158/1078-0432.CCR-09-0767",
language = "English (US)",
volume = "15",
pages = "6852--6861",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer

AU - Byers, Lauren Averett

AU - Sen, Banibrata

AU - Saigal, Babita

AU - Diao, Lixia

AU - Wang, Jing

AU - Nanjundan, Meera

AU - Cascone, Tina

AU - Mills, Gordon

AU - Heymach, John V.

AU - Johnson, Faye M.

PY - 2009/11/15

Y1 - 2009/11/15

N2 - Purpose: Signal transducer and activator of transcription-3 (STAT3) is downstream of growth factor and cytokine receptors, and regulates key oncogenic pathways in non-small cell lung cancer (NSCLC). Activation of STAT3 by cellular Src (c-Src) promotes tumor progression. We hypothesized that c-Src inhibition could activate STAT3 by inducing a homeostatic feedback loop, contributing to c-Src inhibitor resistance. Experimental Design: The effects of c-Src inhibition on total and phosphorylated STAT3 were measured in NSCLC cell lines and in murine xenograft models by Western blotting. c-Src and STAT3 activity as indicated by phosphorylation was determined in 46 human tumors and paired normal lung by reverse phase protein array. Modulation of dasatinib (c-Src inhibitor) cytotoxicity by STAT3 knockdown was measured by MTT, cell cycle, and apoptosis assays. Results: Depletion of c-Src by small interfering RNA or sustained inhibition by dasatinib increased pSTAT3, which could be blocked by inhibition of JAK. Similarly, in vivo pSTAT3 levels initially decreased but were strongly induced after sustained dasatinib treatment. In human tumors, phosphorylation of the autoinhibitory site of c-Src (Y527) correlated with STAT3 phosphorylation (r = 0.64; P = 2.5 x 10-6). STAT3 knockdown enhanced the cytotoxicity of dasatinib. Conclusions: c-Src inhibition leads to JAK-dependent STAT3 activation in vitro and in vivo. STAT3 knockdown enhances the cytotoxicity of dasatinib, suggesting a compensatory pathway that allows NSCLC survival. Data from human tumors showed a reciprocal regulation of c-Src and STAT3 activation, suggesting that this compensatory pathway functions in human NSCLC. These results provide a rationale for combining c-Src and STAT3 inhibition to improve clinical responses.

AB - Purpose: Signal transducer and activator of transcription-3 (STAT3) is downstream of growth factor and cytokine receptors, and regulates key oncogenic pathways in non-small cell lung cancer (NSCLC). Activation of STAT3 by cellular Src (c-Src) promotes tumor progression. We hypothesized that c-Src inhibition could activate STAT3 by inducing a homeostatic feedback loop, contributing to c-Src inhibitor resistance. Experimental Design: The effects of c-Src inhibition on total and phosphorylated STAT3 were measured in NSCLC cell lines and in murine xenograft models by Western blotting. c-Src and STAT3 activity as indicated by phosphorylation was determined in 46 human tumors and paired normal lung by reverse phase protein array. Modulation of dasatinib (c-Src inhibitor) cytotoxicity by STAT3 knockdown was measured by MTT, cell cycle, and apoptosis assays. Results: Depletion of c-Src by small interfering RNA or sustained inhibition by dasatinib increased pSTAT3, which could be blocked by inhibition of JAK. Similarly, in vivo pSTAT3 levels initially decreased but were strongly induced after sustained dasatinib treatment. In human tumors, phosphorylation of the autoinhibitory site of c-Src (Y527) correlated with STAT3 phosphorylation (r = 0.64; P = 2.5 x 10-6). STAT3 knockdown enhanced the cytotoxicity of dasatinib. Conclusions: c-Src inhibition leads to JAK-dependent STAT3 activation in vitro and in vivo. STAT3 knockdown enhances the cytotoxicity of dasatinib, suggesting a compensatory pathway that allows NSCLC survival. Data from human tumors showed a reciprocal regulation of c-Src and STAT3 activation, suggesting that this compensatory pathway functions in human NSCLC. These results provide a rationale for combining c-Src and STAT3 inhibition to improve clinical responses.

UR - http://www.scopus.com/inward/record.url?scp=72549108620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72549108620&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-0767

DO - 10.1158/1078-0432.CCR-09-0767

M3 - Article

VL - 15

SP - 6852

EP - 6861

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 22

ER -